CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (89,165)	$ (188,140)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to the sales of future royalties	(32,298)	(32,693)
Non-cash interest expense on liabilities related to the sales of future royalties	11,939	12,557
Stock-based compensation	11,418	17,985
Depreciation and amortization	3,066	4,468
Deferred income tax expense	19	(1,839)
Impairment of right-of-use assets and property, plant and equipment	8,329	26,455
Impairment of goodwill	0	76,501
Provision for net realizable value of inventory	2,567	1,252
Amortization of premiums (discounts), net and other non-cash transactions	(5,647)	(8,150)
Changes in operating assets and liabilities:
Accounts receivable	9	4,646
Inventory	(931)	(2,739)
Operating leases, net	(4,196)	(3,717)
Other assets	1,817	7,902
Accounts payable	(3,266)	(9,997)
Accrued expenses	10,749	(7,929)
Net cash used in operating activities	(85,590)	(103,438)
Cash flows from investing activities:
Purchases of investments	(173,504)	(249,724)
Maturities of investments	210,087	316,088
Purchases of property, plant and equipment	(343)	(595)
Net cash provided by investing activities	36,240	65,769
Cash flows from financing activities:
Proceeds from shares issued under equity compensation plans	22	18
Proceeds from issuance of pre-funded warrant	30,000	0
Proceeds from sale of future royalties	15,000	0
Repurchase of common stock from Bristol-Myers Squibb	(3,000)	0
Net cash provided by financing activities	42,022	18
Effect of foreign exchange rates on cash and cash equivalents	(9)	152
Net increase (decrease) in cash and cash equivalents	(7,337)	(37,499)
Cash and cash equivalents at beginning of period	35,277	88,227
Cash and cash equivalents at end of period	$ 27,940	$ 50,728